OBG3 globular head and uses thereof
View Patent ↗The present invention relates to the field of obesity research. Obesity is a public health problem that is serious and widespread. The application is related to OBG3 polypepide fragments and compositions comprising these fragments. It also discloses methods of reducing free fatty acid levels with the polypeptide fragments of the invention.
1. An isolated polypeptide consisting of consecutive amino acids: 87-244 of SEQ ID NO: 6, 88-244 of SEQ ID NO: 6, 89-244 of SEQ ID NO: 6, 90-244 of SEQ ID NO: 6, 91-244 of SEQ ID NO: 6, 92-244 of SEQ ID NO: 6, 93-244 of SEQ ID NO: 6, 94-244 of SEQ ID NO: 6, 95-244 of SEQ ID NO: 6, 96-244 of SEQ ID NO: 6, 97-244 of SEQ ID NO: 6, 98-244 of SEQ ID NO: 6, 99-244 of SEQ ID NO: 6, 100-244 of SEQ ID NO: 6, 111-191 of SEQ ID NO: 6, 144-199 of SEQ ID NO: 6, 191-244 of SEQ ID NO: 6, 108 to 244 of SEQ ID NO: 6 or amino acids 108 to 244 of SEQ ID NO: 6 to which an N-terminal methionine has been added.
2. The isolated polypeptide according to claim 1 , wherein said polypeptide consists of consecutive amino acids 87-244 of SEQ ID NO: 6.
3. The isolated polypeptide according to claim 1 , wherein said polypeptide consists of consecutive amino acids 88-244 of SEQ ID NO: 6.
4. The isolated polypeptide according to claim 1 , wherein said polypeptide consists of consecutive amino acids 89-244 of SEQ ID NO: 6.
5. The isolated polypeptide according to claim 1 , wherein said polypeptide consists of consecutive amino acids 90-244 of SEQ ID NO: 6.
6. The isolated polypeptide according to claim 1 , wherein said polypeptide consists of consecutive amino acids 91-244 of SEQ ID NO: 6.
7. The isolated polypeptide according to claim 1 , wherein said polypeptide consists of consecutive amino acids 92-244 of SEQ ID NO: 6.
8. The isolated polypeptide according to claim 1 , wherein said polypeptide consists of consecutive amino acids 93-244 of SEQ ID NO: 6.
9. The isolated polypeptide according to claim 1 , wherein said polypeptide consists of consecutive amino acids 94-244 of SEQ ID NO: 6.
10. The isolated polypeptide according to claim 1 , wherein said polypeptide consists of consceutive amino acids 95-244 of SEQ ID NO: 6.
11. The isolated polypeptide according to claim 1 , wherein said polypeptide consists of consecutive amino acids 96-244 of SEQ ID NO: 6.
12. The isolated polypeptide according to claim 1 , wherein said polypeptide consists of consecutive amino acids 97-244 of SEQ ID NO: 6.
13. The isolated polypeptide according to claim 1 , wherein said polypeptide consists of consecutive amino acids 98-244 of SEQ ID NO: 6.
14. The isolated polypeptide according to claim 1 , wherein said polypeptide consists of consecutive amino acids 99-244 of SEQ ID NO: 6.
15. The isolated polypeptide according to claim 1 , wherein said polypeptide consists of consecutive amino acids 100-244 of SEQ ID NO: 6.
16. The isolated polypeptide according to claim 1 , wherein said polypeptide consists of consecutive amino acids 111-191 of SEQ ID NO: 6.
17. The isolated polypeptide according to claim 1 , wherein said polypeptide consists of consecutive amino acids 144-199 of SEQ ID NO: 6.
18. The isolated polypeptide according to claim 1 , wherein said polypeptide consists of consecutive amino acids 191-244 of SEQ ID NO: 6.
19. The isolated polypeptide according to claim 1 , wherein said polypeptide consists of consecutive amino acids 108-244 of SEQ ID NO: 6.
20. The isolated polypeptide according to claim 1 , wherein said polypeptide consists of consecutive amino acids 108 to 244 of SEQ ID NO: 6 to which an N-terminal methionine has been added.
21. A composition comprising a carrier and a polypeptide consisting of consecutive amino acids: 87-244 of SEQ ID NO: 6, 88-244 of SEQ ID NO: 6, 89-244 of SEQ ID NO: 6, 90-244 of SEQ ID NO: 6, 91-244 of SEQ ID NO: 6, 92-244 of SEQ ID NO: 6, 93-244 of SEQ ID NO: 6, 94-244 of SEQ ID NO: 6, 95-244 of SEQ ID NO: 6, 96-244 of SEQ ID NO: 6, 97-244 of SEQ ID NO: 6, 98-244 of SEQ ID NO: 6, 99-244 of SEQ ID NO: 6, 100-244 of SEQ ID NO: 6, 111-191 of SEQ ID NO: 6, 144-199 of SEQ ID NO: 6, 191-244 of SEQ ID NO: 6, 108 to 244 of SEQ ID NO: 6 or amino acids 108 to 244 of SEQ ID NO: 6 to which an N-terminal methionine has been added.
22. The composition according to claim 21 , wherein said polypeptide consists of consecutive amino acids 87-244 of SEQ ID NO: 6.
23. The composition according to claim 21 , wherein said polypeptide consists of consecutive amino acids 88-244 of SEQ ID NO: 6.
24. The composition according to claim 21 , wherein said polypeptide consists of consecutive amino acids 89-244 of SEQ ID NO: 6.
25. The composition according to claim 21 , wherein said polypeptide consists of consecutive amino acids 90-244 of SEQ ID NO: 6.
26. The composition according to claim 21 , wherein said polypeptide consists of consecutive amino acids 91-244 of SEQ ID NO: 6.
27. The composition according to claim 21 , wherein said polypeptide consists of consecutive amino acids 92-244 of SEQ ID NO: 6.
28. The composition according to claim 21 , wherein said polypeptide consists of consecutive amino acids 93-244 of SEQ ID NO: 6.
29. The composition according to claim 21 , wherein said polypeptide consists of consecutive amino acids 94-244 of SEQ ID NO: 6.
30. The composition according to claim 21 , wherein said polypeptide consists of consecutive amino acids 95-244 of SEQ ID NO: 6.
31. The composition according to claim 21 , wherein said polypeptide consists of consecutive amino acids 96-244 of SEQ ID NO: 6.
32. The composition according to claim 21 , wherein said polypeptide consists of consecutive amino acids 97-244 of SEQ ID NO: 6.
33. The composition according to claim 21 , wherein said polypeptide consists of consecutive amino acids 98-244 of SEQ ID NO: 6.
34. The composition according to claim 21 , wherein said polypeptide consists of consecutive amino acids 99-244 of SEQ ID NO: 6.
35. The composition according to claim 21 , wherein said polypeptide consists of consecutive amino acids 100-244 of SEQ ID NO: 6.
36. The composition according to claim 21 , wherein said polypeptide consists of consecutive amino acids 111-191 of SEQ ID NO: 6.
37. The composition according to claim 21 , wherein said polypeptide consists of consecutive amino acids 144-199 of SEQ ID NO: 6.
38. The composition according to claim 21 . wherein said polypeptide consists of consecutive amino acids 191-244 of SEQ ID NO: 6.
39. The composition according to claim 21 , wherein said polypeptide consists of consecutive amino acids 108-244 of SEQ ID NO: 6.
40. The composition according to claim 21 , wherein said polypeptide consists of consecutive amino acids 108to 244 of SEQ ID NO: 6 to which an N-terminal methionine has been added.
41. A method of reducing free fatty acid levels in an individual comprising administering an effective amount of a composition comprising carrier and a polypeptide consisting of consecutive amino acids: 87-244 of SEQ ID NO: 6, 88-244 of SEQ ID NO: 6, 89-244 of SEQ ID NO: 6, 90-244 of SEQ ID NO: 6, 91-244 of SEQ ID NO: 6, 92-244 of SEQ ID NO: 6, 93-244 of SEQ ID NO: 6, 94-244 of SEQ ID NO: 6, 95-244 of SEQ ID NO: 6, 96-244 of SEQ ID NO: 6, 97-244 of SEQ ID NO: 6, 98-244 of SEQ ID NO: 6, 99-244 of SEQ ID NO: 6, 100-244 of SEQ ID NO: 6, 111-191 of SEQ ID NO: 6, 144-199 of SEQ ID NO: 6, 191-244 of SEQ ID NO: 6, 108 to 244 of SEQ ID NO: 6 or amino acids 108 to 244 of SEQ ID NO: 6 to which an N-terminal methionine has been added.
42. The method according to claim 41 , wherein said composition comprises a carrier and a polypeptide that consists of consecutive amino acids 87-244 of SEQ ID NO: 6.
43. The method according to claim 41 , wherein said composition comprises a carrier and a polypeptide that consists of consecutive amino acids 88-244 of SEQ ID NO: 6.
44. The method according to claim 41 , wherein said composition comprises a carrier and a polypeptide that consists of consecutive amino acids 89-244 of SEQ ID NO: 6.
45. The method according to claim 41 , wherein said composition comprises a carrier and a polypeptide that consists of consecutive amino acids 90-244 of SEQ ID NO: 6.
46. The method according to claim 41 , wherein said composition comprises a carrier and a polypeptide that consists of consecutive amino acids 91-244 of SEQ ID NO: 6.
47. The method according to claim 41 , wherein said composition comprises a carrier and a polypeptide that consists of consecutive amino acids 92-244 of SEQ ID NO: 6.
48. The method according to claim 41 , wherein said composition comprises a carrier and a polypeptide that consists of consecutive amino acids 93-244 of SEQ ID NO: 6.
49. The method according to claim 41 , wherein said composition comprises a carrier and a polypeptide that consists of consecutive amino acids 94-244 of SEQ ID NO: 6.
50. The method according to claim 41 , wherein said composition comprises a carrier and a polypeptide that consists of consecutive amino acids 95-244 of SEQ ID NO: 6.
51. The method according to claim 41 , wherein said composition comprises a carrier and a polypeptide that consists of consecutive amino acids 96-244 of SEQ ID NO: 6.
52. The method according to claim 41 , wherein said composition comprises a carrier and a polypeptide that consists of consecutive amino acids 97-244 of SEQ ID NO: 6.
53. The method according to claim 41 , wherein said composition comprises a carrier and a polypeptide that consists of consecutive amino acids 98-244 of SEQ ID NO: 6.
54. The method according to claim 41 , wherein said composition comprises a carrier and a polypeptide that consists of consecutive amino acids 99-244 of SEQ ID NO: 6.
55. The method according to claim 41 , wherein said composition comprises a carrier and a polypeptide that consists of consecutive amino acids 100-244 of SEQ ID NO: 6.
56. The method according to claim 41 , wherein said composition comprises a carrier and a polypeptide that consists of consecutive amino acids 111-191 of SEQ ID NO: 6.
57. The method according to claim 41 , wherein said composition comprises a carrier and a polypeptide that consists of consecutive amino acids 144-199 of SEQ ID NO: 6.
58. The method according to claim 41 , wherein said composition comprises a carrier and a polypeptide that consists of consecutive amino acids 191-244 of SEQ ID NO: 6.
59. The method according to claim 41 , wherein said composition comprises a carrier and a polypeptide that consists of consecutive amino acids 108-244 of SEQ ID NO: 6.
60. The method according to claim 41 , wherein said composition comprises a carrier and a polypeptide that consists of consecutive amino acids 108 to 244 of SEQ ID NO: 6 to which an N-terminal methionine has been added.